1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward

When it comes to planning studies for your drug’s preclinical development, even more due diligence is required because the stakes could be huge. You can’t just pull into another dealership and drive out with a new molecule. Data quality, expertise of whoever is conducting the study, and confidence in interpretation of results should be at the top of the list for considerations for safety studies because inaccuracies or missed red flags early in development could result in big problems or even failure down the road.